Healthcare Sales & Marketing Network News: m3

Searching News Database: m3

HSMN NewsFeed - 18 Feb 2026
Mammotome Launches First In-Room MR Vacuum-Assisted Breast Biopsy System
Devices Product Launch

HSMN NewsFeed - 6 Feb 2026
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals

HSMN NewsFeed - 11 Aug 2021
Stryker Launches SurgiCount+ Safety-Sponge System
Devices Surgery Product Launch

HSMN NewsFeed - 3 Aug 2021
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
Biopharmaceuticals

HSMN NewsFeed - 28 Jul 2021
Medtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring
Devices Cardiology FDA

HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals

HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 4 Dec 2020
Marizyme, Inc. Expands Executive Team, Board of Directors
Devices Surgery Cardiology Personnel

HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 1 Jul 2020
Engage Surgical Announces FDA 510(k) Clearance And Limited Market Release Of The Cementless Engage(TM) Partial Knee System
Devices Orthopaedic FDA

HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Sep 2019
Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System
Devices Oncology Product Launch

HSMN NewsFeed - 21 May 2019
Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar(R) Gel
Biopharmaceuticals Reimbursement Litigation

HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Feb 2019
AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Oct 2018
Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results
Diagnostics FDA Product Launch

HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Oct 2018
HCG is First in India to Treat Cancer Patients Using the Accuray Radixact(R) System
Devices Oncology

HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Aug 2018
Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jun 2018
Steba Biotech's TOOKAD(R) Vascular Photodynamic Therapy Maintains Significant Reduction in Overall Progression and Conversion to Radical Therapy in Low-risk Prostate Cancer Patients at 4 Years
Biopharmaceuticals Urology Oncology

HSMN NewsFeed - 6 Jun 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine(R) (sargramostim) for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 May 2018
Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 May 2018
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Apr 2018
Hill-Rom Enhances Spot(TM) Vision Screener To Serve Senior Population
Devices Ophthalmology Product Launch

HSMN NewsFeed - 15 Mar 2018
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Biopharmaceuticals Oncology Urology FDA

HSMN NewsFeed - 7 Feb 2018
Abbott's App for FreeStyle(R) Libre System Now Available in Europe for Both iPhone and Android
Devices Monitoring Endocrinology Product Launch

HSMN NewsFeed - 1 Feb 2018
Partner Therapeutics (PTx) Acquires Leukine(R) from Sanofi
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Dec 2017
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Aug 2017
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 9 Jun 2017
Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 16 May 2017
Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience
Devices Interventional Cardiology

HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 1 Mar 2017
Athenex Inc. announces the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Dec 2016
AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Nov 2016
Athenex and Lilly Enter Clinical Collaboration Agreement
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Aug 2016
Takeda Receives Marketing Authorization in Canada for NINLARO(TM) (ixazomib) in Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals

HSMN NewsFeed - 19 May 2016
TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients' Neurological Outcomes in TAVR Procedures
Devices Interventional Cardiology Neurology

HSMN NewsFeed - 19 Feb 2016
Novogen Patent Covering Cantrixil and Trilexium has Proceeded to Grant
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jan 2016
Steba Biotech Completes its European Phase 3 Clinical Trial of TOOKAD(R) in Patients with Low-Risk Prostate Cancer and Submits Marketing Authorization Application to the European Medicine Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Dec 2014
Novartis gains FDA approval for Signifor(R) LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jun 2014
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
Biopharmaceuticals

HSMN NewsFeed - 13 Feb 2014
MYOS Corporation Announces Appointment of Robert C. Ashton, Jr., M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Nov 2013
Smith & Nephew Introduces Advanced Biocomposite Material for Use in Arthroscopic Surgery
Devices Orthopaedic Product Launch

HSMN NewsFeed - 16 May 2013
Colibri Heart Valve to Present Six Month Follow-up Results from First Clinical Use at Upcoming EuroPCR Meeting
Devices Interventional Cardiology

HSMN NewsFeed - 10 Apr 2013
Pfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jan 2013
Encision Launches Three New Products, Including the EM3 AEM(R) Monitor
Devices Monitoring Surgery Product Launch

HSMN NewsFeed - 8 Nov 2012
joimax(R), EndoSphere Spine, LLC and the University of Toledo, Ohio, Have Signed a License Agreement on Endoscopic Cage Technologies
Devices Neurosurgery Orthopaedic Licensing

HSMN NewsFeed - 8 Jun 2012
Aircraft Medical Launches the McGRATH(R) MAC 2 Blade for Paediatric Patients
Devices

HSMN NewsFeed - 17 May 2012
Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent(TM) Compared to the TAXUS(R) Stent Shown in Two Clinical Trial Subgroup Analyses
Devices Interventional Cardiology

HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Feb 2012
Plexxikon Announces European Approval of Zelboraf(R) for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Aug 2011
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
Biopharmaceuticals Oncology Personalized Medicine FDA

HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 7 Feb 2011
OSI Systems Receives $2.3 Million Patient Monitoring Contract from Princeton HealthCare System
Devices Monitoring

HSMN NewsFeed - 19 Jan 2011
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
Biopharmaceuticals Diagnostics Personalized Medicine

HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2010
OSI Systems Announces Introduction of Spacelabs Healthcare Ultraview DM3 Dual-Mode Vital Signs Monitor
Devices Monitoring

HSMN NewsFeed - 15 Apr 2010
Comparative Trial of Canyon's Iprivask(R) (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT
Biopharmaceuticals

HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Feb 2010
Medicis Receives Approval for RESTYLANE(R) and PERLANE(R) With Lidocaine
Devices Dermatology FDA

HSMN NewsFeed - 29 Jan 2010
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 7 Jan 2010
Forest and Almirall Announce Positive Results from the ACCORD COPD I Phase III Study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals

HSMN NewsFeed - 15 Sep 2009
European Union Commission Approves Expanded Use of ISENTRESS(R) (raltegravir), from MSD, in Adult Patients with HIV-1 Infection
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 17 Aug 2009
Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
Biopharmaceuticals

HSMN NewsFeed - 17 Aug 2009
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology

HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Feb 2009
PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 8 Oct 2008
Natus Medical to Acquire Products from BrainZ Instruments Limited
Devices Monitoring Acquisitions

HSMN NewsFeed - 3 Sep 2008
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals

HSMN NewsFeed - 2 Sep 2008
New Data Shows Anticlotting Medicine, AGGRASTAT(R), Lowers Incidence of Heart Attack, in Patients Who Respond Poorly to Aspirin or Clopidogrel, after Elective Coronary Angioplasty
Biopharmaceuticals Cardiology

HSMN NewsFeed - 29 Aug 2008
INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Aug 2008
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Aug 2008
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 11 Jul 2008
Momenta Pharmaceuticals Announces Filing of Abbreviated New Drug Application With a Paragraph IV Certification for Generic Version of Copaxone
Biopharmaceuticals Generics Neurology FDA

HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2008
Bayer Announces Availability of Reformulated Liquid Leukine(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 May 2008
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Feb 2008
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Feb 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Feb 2008
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 6 Feb 2008
Merck's ISENTRESS(R) (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 21 Dec 2007
ISENTRESS(R) (raltegravir) from MSD, First Integrase Inhibitor, Approved by the European Union Commission
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 28 Nov 2007
Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 18 Sep 2007
ISENTRESS(TM) (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 27 Jul 2007
Positive Aggrastat(R) Results Versus Integrilin(R) Featured in American Heart Journal
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 25 Jul 2007
New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show Similar Efficacy and Lipid Changes
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 25 Jul 2007
Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 22 Jun 2007
Barr Receives Approval for Generic VESANOID(R) Capsules, 10 mg
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 14 Jun 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 3 Jun 2007
CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2007
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Urology

HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals

HSMN NewsFeed - 26 Mar 2007
Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
Biopharmaceuticals Cardiology

HSMN NewsFeed - 1 Mar 2007
Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 1 Mar 2007
Results from Two Phase III Studies on ISENTRESS(TM) (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 16 Feb 2007
Anti-HIV Medication PREZISTA(TM) Receives Conditional Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 12 Dec 2006
New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals

HSMN NewsFeed - 12 Dec 2006
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Nov 2006
More Than 2 Million Cancer Patients Treated with BrainLAB m3(R) Shaped Beam Radiosurgery
Devices Oncology

HSMN NewsFeed - 24 Oct 2006
Philips Announces Availability of Triplets Monitoring with Its Avalon Fetal Monitors; Company is first to introduce triplets monitoring using one fetal monitor
Devices Monitoring

HSMN NewsFeed - 20 Oct 2006
Lilly Launches Phase III 'GALES' Trial of ALIMTA(R) (Pemetrexed for Injection) in Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Oct 2006
FDA Grants Priority Review for ARIXTRA(R) (fondaparinux sodium) in the Treatment of Acute Coronary Syndromes
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 2 Oct 2006
Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT)
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Sep 2006
New Data Reinforce Efficacy of TRIZIVIR(R) Alone in Treatment-Naive HIV Patients with Low Viral Load
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 7 Sep 2006
The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX(R)(Enoxaparin Sodium Injection) Vs. Unfractionated Heparin in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention (PCI)
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 12 Jul 2006
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Biopharmaceuticals FDA HIV/AIDS

HSMN NewsFeed - 23 May 2006
New Data Show Overactive Bladder Therapy Enablex(R) Does Not Impair Memory Function Compared to Frequently Used Alternative
Biopharmaceuticals Urology Neurology

Return to NewsFeed

Additional items found! 73

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 73 additional stories matching:
m3
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.